Overview

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2027-07-20

Target enrollment:

Participant gender:

Summary

This randomized phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk asymptomatic (smoldering) multiple myeloma. Biological therapies such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether lenalidomide is effective in treating patients with high-risk smoldering multiple myeloma than observation alone.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Lenalidomide
Thalidomide